News | Artificial Intelligence | February 23, 2021

icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio

icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio

February 23, 2021 — icometrix, world leader in imaging artificial intelligence (AI) solutions for people with neurological conditions, announced the addition of icobrain cva, a stroke solution, to the icobrain portfolio. The announcement follows the FDA-clearance and CE-marking of its image processing software for the analysis and communication of the tissue perfusion state on computed tomography (CT) perfusion scans in patients with ischemic stroke. icobrain cva provides physicians with fast, fully automated, and state-of-the-art insights to support treatment decisions in acute ischemic stroke.

Since 2018, treatment guidelines for stroke have expanded the treatment window for mechanical thrombectomy from 6 to 24 hours. Treatment for ischemic stroke is not without risk and requires careful patient selection based on their tissue status. The automated assessment of tissue parameters in an acute clinical setting by icobrain cva will allow more patients to get the right treatment and can improve patient outcomes and care while increasing efficiency.

"With the launch of icobrain cva we address a persisting need in the treatment of acute ischemic stroke. By democratizing advanced CT perfusion analysis for healthcare systems worldwide we take the next step in our mission to become a holistic brain solution provider," said Wim Van Hecke, CEO at icometrix.

"The main challenge of current stroke solutions is correctly identifying the entry point of the injected contrast in the brain. icobrain cva introduces new, patented, deep learning technology into this identification process to achieve a more robust assessment of the infarcted area," explained Dirk Smeets, CTO at icometrix.

icobrain cva is a fully-automated CE-marked and FDA-cleared software solution for the quantitative assessment of tissue perfusion on CT. icobrain cva reports the volume of the core and perfusion lesion by quantifying reduced cerebral blood flow, volume, and transit time. The report includes information on the correctness of the selected arterial input function and the quality of the output. icobrain cva is a cloud-based solution, returning a report and perfusion maps straight into your PACS and e-mail inbox.

For more information: icometrix.com


Related Content

News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | ARRS

Feb. 11, 2026 —The American Roentgen Ray Society (ARRS) has announced the following radiologists, as well as their ...

Time February 13, 2026
arrow
News | Digital Pathology

Feb. 11, 2026 — Leica Biosystems has announced the global launch of the Leica CM1950 Cryostat with DualEcoTec Cooling ...

Time February 11, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 9, 2026 — MRIguidance, a MedTech company developing BoneMRI, a radiation-free bone imaging solution, has appointed ...

Time February 09, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | Interventional Radiology

Feb. 2, 2026 — GE HealthCare has announced that Allia Moveo has received U.S. Food and Drug Administration (FDA) 510(k) ...

Time February 02, 2026
arrow
News | Radiology Imaging

Jan.26, 2026 — SimonMed Imaging has unveiled an updated brand and the launch of SimonMed Longevity, a new division ...

Time January 27, 2026
arrow
Subscribe Now